Tardive Dyskinesia: Finally Some Good News

摘要

By now, nearly every one of us is sick of trying to decipher the recent news reports for veracity. But fear not, here’s one that is guaranteed to be true. Just a few weeks ago, the FDA approved valbenazine (to be marketed as Ingrezza by Neurocrine Biosciences) as the first treatment specifically indicated for tardive dyskinesia (TD).1